📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

34 Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 trial (2024)

First Author: Wu X

Attributed to: Face Matching for Automatic Identity Retrieval, Recognition, Verification and Management funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1136/ijgc-2024-esgo.556

Publication URI: http://dx.doi.org/10.1136/ijgc-2024-esgo.556

Type: Conference/Paper/Proceeding/Abstract

ISSN: 1048-891X